PRINCETON, N.J., Aug. 7, 2011 /PRNewswire/ — Pharmasset, Inc.
(Nasdaq:
VRUS) announces that management will present at the Canaccord
Genuity Growth Conference to be held August 10 to 11, 2011 at the
Intercontinental Hotel, Boston, Massachusetts. Schaefer Price,
Pharmasset’s President and Chief Executive Officer, will provide an
overview of the company at the Canaccord Genuity conference on
Thursday, August 11, 2011 at 9:30 AM (ET).
To access a simultaneous webcast of Mr. Price’s overview via the
internet, log on to the “Events & Presentations” section of the
Investor Center on Pharmasset’s website at http://investor.pharmasset.com/events.cfm.
Please connect to the website at least ten minutes prior to the
start of the presentation to ensure adequate time for a reliable
connection and any software download that may be necessary for the
webcast.
A replay of the webcasts will be available on Pharmasset’s
website for thirty days following the conference. The investor
presentation will be available for download in PDF format
immediately following the presentation in the “Events &
Presentations” section of the Investor Center on Pharmasset’s
website at http://investor.pharmasset.com/events.cfm.
About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed
to discovering, developing, and commercializing novel drugs to
treat viral infections. Pharmasset’s primary focus is the
development of oral therapeutics for the treatment of hepatitis C
virus (HCV) infection. Our research and development efforts are
focused on nucleoside/tide analogs, a class of compounds which act
as alternative substrates for the viral polymerase, thus inhibiting
viral replication. We currently have three clinical-stage product
candidates adv
‘/>”/>
SOURCE
